Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

MYSTERIOUS: Crispr therapeutics s return on capital employed insights | Mind Blowing Facts

Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter. In Q3, CRISPR Therapeutics brought in $824.00 thousand in sales but lost $127.15 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.